ClinicalTrials.gg
Drug

PF-06651600 clinical trials

Also written PF-06651600, Ritlecitinib and Litfulo.

studies test it
46
open now
4
in phase 3
7
first study started
2016

How each study uses PF-06651600 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the PF-06651600 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
23 Jun 2023 · LITFULO · NDA 215830 (FDA, Drugs@FDA)
European Union
15 Sept 2023 · Litfulo · EMEA/H/C/006025 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Brand

Litfulo
2

Development codes

PF-06651600
30

Other names

Ritlecitinib
16
Ritlecitinib 100 mg
4
Ritlecitinib 50 mg
4
Ritlecitinib 20 mg
1
Ritlecitinib 200 mg
1

Studies by the year they started

46 studies that test it; most in 2019 (10)

Studies that test PF-06651600, by start year
YearStudies
20163
20172
20185
201910
20206
20213
20222
20236
20244
20254
20261

By phase

A phase 1/2 study counts in both.

Phase 1
24
Phase 2
16
Phase 3
7

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 40 · Other 6

Pfizer (40) · Icahn School of Medicine at Mount Sinai (2) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · Massachusetts General Hospital (1) · Emma Guttman (1) · Ahuva D Cices (1)

Often tested with

Tested in the same studies.

PF-06700841 (4) · Zimlovisertib (2) · Abrocitinib (1) · Tolbutamide (1) · Tofacitinib (1) · Contraceptives, Oral (1) · Midazolam (1) · Efavirenz (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 5, 2 in phase 3

Studies that test PF-06651600, phase 3 first.

Studies

Open first, then newest update. How each study uses PF-06651600 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 46

See all 46 studies that test PF-06651600 →

As the comparator · 1 — what is tested is compared with PF-06651600

Codes

What other systems call PF-06651600 · ClinicalTrials.gg INT000617

Also registered as ritlecitinib tosylate (UNII EAG4T1459K).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.